Silver Book Fact

Use of an epidermal growth factor inhibitor in the treatment of metastatic colon cancer patients without the KRAS gene mutation saw survival rates of 15.6 months, compared to 5.6 months in those without the mutation.

Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al. KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab. J Clin Oncol. 2008; 26(3): 374-9. http://www.ncbi.nlm.nih.gov/pubmed/18202412

Reference

Title
KRAS Mutations as an Independent Prognostic Factor in Patients with Advanced Colorectal Cancer Treated with Cetuximab
Publication
J Clin Oncol
Publication Date
2008
Authors
Lievre, A, J Bachet, V Boige, A Cayre, D LeCorre, E Buc, et al
Volume & Issue
Volume 26, Issue 3
Pages
374-9
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A one percent reduction in cancer-related deaths in the U.S. would be worth an estimated $500 billion to society from increased quality of life and increased productivity from longer lives.  
  • More than half of cancer deaths in the U.S. are due to preventable causes.  
  • If the use of recommended colorectal screening increased to 70.5 percent, 1,000 additional lives could be saved each year.  
  • A one percent reduction in lung, colorectal, breast, leukemia, pancreatic, and brain cancer mortality would reduce productivity costs by $814 million per year.  
  • Incidence rates for colorectal cancer have been decreasing since 1985, from 66 to 52 per 100,000 in 2002.